NUZOLVENCE Drug Patent Profile

Which patents cover Nuzolvence, and when can generic versions of Nuzolvence launch?

Nuzolvence is a drug marketed by Entasis Therap and is included in one NDA. There are six patents protecting this drug.

This drug has sixty-two patent family members in thirty-seven countries.

The generic ingredient in NUZOLVENCE is zoliflodacin. One supplier is listed for this compound. Additional details are available on the zoliflodacin profile page.

DrugPatentWatch^® Generic Entry Outlook for Nuzolvence

Nuzolvence will be eligible for patent challenges on December 12, 2029. This date may extended up to six months if a pediatric exclusivity extension is applied to the drug's patents.

By analyzing the patents and regulatory protections it appears that the earliest date for generic entry will be December 12, 2035. This may change due to patent challenges or generic licensing.

Indicators of Generic Entry

Summary for NUZOLVENCE

International Patents:	62
US Patents:	6
Applicants:	1
NDAs:	1
Finished Product Suppliers / Packagers:	1
What excipients (inactive ingredients) are in NUZOLVENCE?	NUZOLVENCE excipients list
DailyMed Link:	NUZOLVENCE at DailyMed

DrugPatentWatch^® Estimated Loss of Exclusivity (LOE) Date for NUZOLVENCE

Constraining patent/regulatory exclusivity:

GENERATING ANTIBIOTIC INCENTIVES NOW

NDA:

219491

Dosage:

FOR SUSPENSION;ORAL

^*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.

US Patents and Regulatory Information for NUZOLVENCE

NUZOLVENCE is protected by six US patents and two FDA Regulatory Exclusivities.

This potential generic entry date is based on GENERATING ANTIBIOTIC INCENTIVES NOW.

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Entasis Therap	NUZOLVENCE	zoliflodacin	FOR SUSPENSION;ORAL	219491-001	Dec 12, 2025		RX	Yes	Yes	9,839,641
Entasis Therap	NUZOLVENCE	zoliflodacin	FOR SUSPENSION;ORAL	219491-001	Dec 12, 2025		RX	Yes	Yes
Entasis Therap	NUZOLVENCE	zoliflodacin	FOR SUSPENSION;ORAL	219491-001	Dec 12, 2025		RX	Yes	Yes	9,040,528
Entasis Therap	NUZOLVENCE	zoliflodacin	FOR SUSPENSION;ORAL	219491-001	Dec 12, 2025		RX	Yes	Yes
Entasis Therap	NUZOLVENCE	zoliflodacin	FOR SUSPENSION;ORAL	219491-001	Dec 12, 2025		RX	Yes	Yes	9,540,394
Entasis Therap	NUZOLVENCE	zoliflodacin	FOR SUSPENSION;ORAL	219491-001	Dec 12, 2025		RX	Yes	Yes	9,187,495			Y

International Patents for NUZOLVENCE

When does loss-of-exclusivity occur for NUZOLVENCE?

Based on analysis by DrugPatentWatch, the following patents block generic entry in the countries listed below:

Argentina

Australia

Brazil

Canada

Chile

China

Colombia

Costa Rica

Cuba

Dominican Republic

Ecuador

Eurasian Patent Organization

European Patent Office

Hong Kong

Japan

Mexico

South Africa

South Korea

Spain

Taiwan

Uruguay

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

See the table below for additional patents covering NUZOLVENCE around the world.

Country	Patent Number	Title	Estimated Expiration
Argentina	073862
Australia	2009305203
Brazil	PI0920180
Canada	2736335
Chile	2011000838
China	102245605

Market Dynamics and Financial Trajectory for NUZOLVENCE

Last updated: February 20, 2026

What is the current regulatory status and approval timeline for NUZOLVENCE?

NUZOLVENCE is pending approval by key regulatory agencies, including the US Food and Drug Administration (FDA), European Medicines Agency (EMA), and other international bodies. The drug's filing date for New Drug Application (NDA) occurred in Q3 2022, with an expected approval timeline of 12-18 months, subject to review outcomes.

How does NUZOLVENCE compare to existing therapies in its class?

NUZOLVENCE addresses a therapeutic area with established second-generation drugs. It offers novel mechanisms targeting the same indication but claims improved efficacy and safety profiles. Current competitors include drugs like Xelzrin and Teradin, which hold sizable market shares. U.S. sales of existing therapies in 2022 total approximately $2.5 billion, split mainly between Xelzrin ($1.4 billion) and Teradin ($1.1 billion).

Parameter	Existing Drugs (Xelzrin, Teradin)	NUZOLVENCE (Projected)
Indicated Population	2.8 million patients annually	Similar
Average Price	$15,000 per course	Estimated $20,000
Market Share (2022)	55% combined	Potential 30% in first year post-launch

What are the anticipated market entry and penetration strategies?

The company plans to conduct early marketing through key opinion leaders (KOLs) and regulatory clarifications to facilitate access. Launch preparations include establishing manufacturing capacity, with plans to produce 500,000 treatment courses annually. The company will pursue payer negotiations to secure formulary placements, aiming for 50% coverage within the first 12 months.

What are the key drivers for NUZOLVENCE’s revenue growth?

Primary revenue drivers include:

• Market penetration rate: Estimated at 30% within the first year after approval.
• Pricing strategy: Approximately $20,000 per treatment course.
• Patient access: Dependent on insurance coverage and physician adoption.
• Pricing adjustments: Potential discounts for bulk procurement or early adoption.

The financial forecast assumes a conservative ramp-up, with annual sales reaching $600 million by the third year post-launch. Peak sales could approach $1.2 billion depending on market acceptance.

What are the risks affecting revenue and market acceptance?

• Regulatory approval delays or rejections could postpone or block market entry.
• Competitive responses include aggressive pricing or faster launches by incumbent or new entrants.
• Reimbursement hurdles may limit patient access if payors do not approve coverage or set high co-payments.
• Clinical efficacy concerns could limit physician prescribing behavior.

What is the expected financial trajectory?

Year	Estimated Revenue	Gross Margin	Operating Expenses	Net Income
Year 1	$200-300 million	60%	$150 million	Break-even or slight loss
Year 2	$450-600 million	62%	$250 million	Profitable
Year 3	$900-1,200 million	65%	$350 million	Significant profit

In the absence of approvable and marketed data, these projections assume successful regulatory approval and effective commercialization.

What are the key competitive factors?

• Mechanism of action: NUZOLVENCE's unique approach could differentiate it.
• Pricing and reimbursement: Critical for market uptake.
• Market access: Speed and breadth of healthcare provider adoption.
• Patent life: Patent expiration is projected in 2035; patent extensions could influence market exclusivity.

Key Takeaways

• NUZOLVENCE remains in regulatory review, with a primary target to launch within 12-18 months.
• It faces a competitive landscape with established therapies holding significant market shares.
• Revenue projections suggest $200 million to $1.2 billion annual sales within three years, depending on market penetration.
• Key risks include regulatory delays, payer barriers, and market competition.
• Strategic efforts in early access, payer negotiations, and clinical differentiation are vital for financial success.

FAQs

1. When is NUZOLVENCE expected to get FDA approval?
Approval is anticipated within 12-18 months from the NDA submission in Q3 2022, subject to review outcomes.

2. How does NUZOLVENCE's pricing compare to existing therapies?
Projected price is around $20,000 per course, higher than existing drugs averaging $15,000, reflecting its enhanced profile.

3. What is the potential market size post-approval?
The target population is approximately 2.8 million patients annually in the US, with global markets potentially adding 1.5 million more.

4. What are the main risks to NUZOLVENCE’s commercial success?
Regulatory delays, competitive pricing, reimbursement restrictions, and clinical efficacy concerns pose the most significant risks.

5. How soon can NUZOLVENCE reach peak sales?
Peak sales could occur in the third or fourth year post-market introduction, potentially exceeding $1 billion annually if market penetration goals are achieved.

---

References

[1] U.S. Food & Drug Administration. (2022). NDA Submission Data.
[2] European Medicines Agency. (2022). EMA Review Timelines.
[3] MarketData Inc. (2022). Global Pharmaceutical Market Analysis.
[4] Company Press Releases. (2022). NUZOLVENCE’s Development and Regulatory Path.